Komori
Nippon Shinyaku (4516) · InitiativeFirst stated

Joint research on RNA structures with イクスフォレストセラピューティクス

First written in FY2026. . Latest entry: FY2026.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Joint research with Ixforest Therapeutics on RNA structure-targeted small-molecule drug discoveryA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026First statedAnnual report

    「Joint research agreement aimed at creating novel drugs targeting RNA structures, including an option to obtain an exclusive license to develop and market small-molecule compounds targeting RNA structures March 2026 Until the date on which it is determined whether a commercialization agreement will be executed」

    In March 2026, we entered into a joint research agreement with イクスフォレストセラピューティクス, including an option to obtain exclusive development and marketing rights for small-molecule compounds targeting RNA structures.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Nippon Shinyaku's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.